Strong clinical evidence is essential, but it does not automatically lead to diagnostic adoption. Clinicians and patients must also trust the technology, understand how it fits into their reality and see credible peers using it successfully.
A diagnostics company can develop a genuinely better way to test, monitor or diagnose, backed by strong clinical evidence and the necessary regulatory approval or clearance. Yet it can still take years to change how clinicians and patients behave.
Not because the innovation is wrong. Because trust does not move at the speed of evidence.
Why diagnostic innovation adoption takes time
Every leap forward is also a leap of faith.
Moving testing out of the central laboratory and into a clinic asks healthcare professionals to change an established workflow. Asking patients to collect their own samples introduces new questions about accuracy, safety and responsibility. Asking a clinician to act on an AI-assisted diagnostic result changes how information is interpreted and decisions are made.
In each case, the clinical argument may be convincing. The technology may work exactly as intended. But the people using it are still being asked to replace a habit or process they have trusted for years.
An airtight clinical case can therefore still lose to a simple reaction:
“This is how we have always done it.”
Why more clinical evidence is not always the answer
The natural response is to publish more evidence.
More studies. More technical documents. More data explaining why the innovation is accurate, safe and effective.
That evidence remains essential. But once the clinical case is already strong, another publication may not address the hesitation that is preventing adoption.
Public guidance on digital and AI-enabled healthcare technologies reflects this wider challenge. Successful adoption depends not only on demonstrating performance, but also on factors such as implementation, acceptability, transparency and trust.
What often moves the remaining sceptics is seeing someone they trust already using the innovation successfully.
That trusted person may be a respected clinician, a colleague from a comparable hospital, a patient with a similar concern or a recognised local expert who understands the realities of that specific market.
How trust-building healthcare content supports adoption
The solution looks less like publishing and more like listening.
Diagnostics companies that successfully support clinical adoption do more than prove that their innovation works. They identify the specific hesitation experienced by each audience and build credible content around it.
Different audiences need different forms of reassurance:
- Clinicians need to understand how the innovation fits into their workflow and supports clinical decision-making.
- Patients need clear, accessible explanations that address practical concerns and build confidence.
- Healthcare decision-makers need relevant proof from comparable organisations, markets and healthcare systems.
One global explainer is rarely able to perform all three jobs.
A technical brochure may explain how a diagnostic solution works. It does not necessarily show a sceptical clinician how another clinical team introduced it successfully. It may not reassure a patient who is uncertain about self-sampling. It may not give a local decision-maker the context needed to support implementation.
Peer-to-peer stories, customer reference content and audience-specific educational materials can bridge that gap between clinical evidence and real-world adoption.
The question diagnostics marketers should ask
The most useful question is not always: “Is our evidence strong enough?” In many cases, it already is.
The better question is: “Whose voice would make the remaining sceptics reconsider their position, and have we created content around that voice?”
That shift changes the role of healthcare marketing.
Instead of repeating the same evidence more loudly, marketing begins identifying the people, experiences and practical concerns that influence adoption.
The objective is not to replace clinical evidence with storytelling. It is to translate that evidence into credible, relevant stories that help different audiences understand what the innovation means for them.
Turning clinical evidence into diagnostic adoption
This is at the core of our Healthcare Marketing work at Living Stone.
We translate strong clinical and technical evidence into specific, trust-building content that supports adoption. That can include peer-to-peer clinician stories, patient education, customer reference programmes, localised market content and sales enablement materials.
The goal is not to make one global message work harder.
It is to create the right message for the right audience, patient by patient, clinician by clinician and market by market.
Is your diagnostic innovation clinically proven but still struggling to gain traction? Explore our Healthcare Marketing approach and discover how audience-specific, trust-building content can help move adoption forward.
Frequently asked questions
Why is clinical evidence not enough to drive diagnostic adoption?
Clinical evidence demonstrates that an innovation is safe and effective. Adoption also requires clinicians, patients and decision-makers to understand the technology, trust it and feel confident changing established behaviour or workflows.
How can healthcare marketing support diagnostic adoption?
Healthcare marketing can translate technical evidence into audience-specific content. Peer stories, patient education, customer references and local market examples help answer the practical concerns that scientific publications alone may not address.
What type of content builds trust in diagnostic innovation?
The strongest content usually combines credible evidence with relevant real-world experience. Examples include clinician testimonials, implementation cases, patient explanations, workflow demonstrations and market-specific customer stories.
